Thursday, June 15, 2017

Gene Therapy - Table of Contents alert Volume 24 Issue 6

If you are unable to see the message below, click here to view.
Gene Therapy

Vigene Bioproduction 

  • Make Gene Therapy Affordable
  • Offering AAV, lenti and adeno vectors for pre-clinical and clinical applications
  • Proven track record in preclinical and GMP Phase I/II clinical materials used in vaccine, cell & gene therapy applications for 13 years
  • Perfect for meeting small-scale aseptic filling-in our BSL-3 viral production area
Learn more


Volume 24, Issue 6 (June 2017)

In this issue
Original Articles
Original Article - Enabling Technologies
Short Communication

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Have you read these highly downloaded articles published by Human Genome Variation, an open access journal providing genome variation reports with an accompanying database? 

Whole-exome sequencing analysis of supernumerary teeth occurrence in Japanese individuals 
Genome-first approach diagnosed Cabezas syndrome via novel CUL4B mutation detection 

Read more open access content >>

Original Articles


Characterization of retroviral infectivity and superinfection resistance during retrovirus-mediated transduction of mammalian cells OPEN

J Liao, Q Wei, J Fan, Y Zou, D Song, J Liu, F Liu, C Ma, X Hu, L Li, Y Yu, X Qu, L Chen, X Yu, Z Zhang, C Zhao, Z Zeng, R Zhang, S Yan, T Wu, X Wu, Y Shu, J Lei, Y Li, W Zhang, J Wang, R R Reid, M J Lee, W Huang, J M Wolf, T-C He and J Wang

Gene Ther 2017 24: 333-341; advance online publication, May 4, 2017; 10.1038/gt.2017.24

Abstract | Full Text

Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo

M L Palma, P Duangkhae, B Douradinha, I F T Viana, P O Rigato, R Dhalia, R B Mailliard, S M Barratt-Boyes, E J M Nascimento, T M Oshiro, A J da Silva Duarte and E T A Marques

Gene Ther 2017 24: 342-352; advance online publication, April 17, 2017; 10.1038/gt.2017.25

Abstract | Full Text

Potential mechanisms of microRNA-141-3p to alleviate chronic inflammatory pain by downregulation of downstream target gene HMGB1: in vitro and in vivo studies

W-S Shen, X-Q Xu, N-N Zhai, Z-S Zhou, J Shao and Y-H Yu

Gene Ther 2017 24: 353-360; advance online publication, April 25, 2017; 10.1038/gt.2017.28

Abstract | Full Text

Original Article - Enabling Technologies


Improved gene delivery to adult mouse spinal cord through the use of engineered hybrid adeno-associated viral serotypes

J J Siu, N J Queen, W Huang, F Q Yin, X Liu, C Wang, D M McTigue and L Cao

Gene Ther 2017 24: 361-369; advance online publication, April 25, 2017; 10.1038/gt.2017.27

Abstract | Full Text

Short Communication


Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery

C Goyvaerts, Y De Vlaeminck, D Escors, S Lienenklaus, M Keyaerts, G Raes and K Breckpot

Gene Ther 2017 24: 370-375; advance online publication, May 25, 2017; 10.1038/gt.2017.30

Abstract | Full Text

Advertisement webcasts

Join us for our upcoming webcast followed by live Q&A: 

Presented by BioPharma Dealmakers

Date: Tuesday, 13 June, 2017
Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST


Sponsored by: Immunomic Therapeutics, Inc., | IsoPlexis | Merus N.V. | Actinium Pharmaceuticals, Inc.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Gene Therapy. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: